| 1.74 0.08 (4.82%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.09 | 1-year : | 2.44 |
| Resists | First : | 1.78 | Second : | 2.09 |
| Pivot price | 1.63  |
|||
| Supports | First : | 1.55 |
Second : | 1.4 |
| MAs | MA(5) : | 1.71  |
MA(20) : | 1.59 |
| MA(100) : | 1.36 |
MA(250) : | 1.35 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 73.8 |
D(3) : | 76.2 |
| RSI | RSI(14): 62.5 |
|||
| 52-week | High : | 1.96 | Low : | 0.89 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SYBX ] has closed below upper band by 27.1%. Bollinger Bands are 65.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.76 - 1.77 | 1.77 - 1.78 |
| Low: | 1.62 - 1.63 | 1.63 - 1.64 |
| Close: | 1.72 - 1.74 | 1.74 - 1.76 |
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Thu, 18 Sep 2025
Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth - simplywall.st
Tue, 12 Nov 2024
Synlogic Reports Third Quarter 2024 Financial Results - GlobeNewswire
Sat, 10 Feb 2024
Synlogic Announces Plan to Cease Operations and Reduce Its Workforce by More Than 90% - SynBioBeta
Thu, 08 Feb 2024
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update - Yahoo Finance
Wed, 27 Sep 2023
Synlogic Announces Reverse Stock Split - Stock Titan
Thu, 11 Aug 2022
Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 11.2 (%) |
| Held by Institutions | 64.6 (%) |
| Shares Short | 29 (K) |
| Shares Short P.Month | 37 (K) |
| EPS | -0.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.08 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -11.2 % |
| Return on Equity (ttm) | -7.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -19.34 |
| PEG Ratio | 0 |
| Price to Book value | 1.61 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|